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Abstract: Introduction: It has been reported that patients with diabetes have a decreased risk for developing prostate
cancer. The study aimed to measure Prostate-specific antigen (PSA) levels among diabetic men who had not
previously been diagnosed with prostate cancer. Methods: A cross-sectional study was carried out in public
hospitals among diabetic men in Aden, Yemen. A predesigned structured questionnaire, including the personal
data as well as physical and clinical characteristics of the study population, such as height, weight, smoking
status, the duration of diabetes, and the type of treatment, was included. Blood samples were collected from
the respondents, and the levels of fasting blood glucose (FBG) and PSA were measured. The data were analyzed
using descriptive and inferential statistics. Results: A total of 145 diabetic male patients were included in this
study. The mean PSA level of the respondents was 2.56 ng/ml. There were significant differences in PSA lev-
els according to patient age (p=0.000). The elderly patients exhibited significantly higher PSA levels than the
younger groups. The PSA levels of smokers (2.60±0.48 ng/ml) were significantly higher (p=0.035) than those of
nonsmokers (2.45±0.65 ng/ml). However, no significant difference was found in PSA levels according to body
mass index (BMI) category, the type of treatment, or the duration of diabetes. Additionally, our results showed
that PSA levels were not significantly correlated with FBG levels. Conclusion: PSA levels were associated with
age and smoking status, but not with BMI, the type of diabetic treatment, the duration of diabetes, or with FBG
levels.
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1. Introduction
Prostate-specific antigen (PSA) is a glycoprotein produced
primarily by the prostate gland, and its regulation is under
the control of androgens and progestins (1, 2). It is a ser-
ine protease with chymotrypsin-like enzymatic activity, and
it has a molecular mass of approximately 30 kilodaltons (kDa)
(1, 2). PSA is a member of the human kallikrein family and is
also known as human kallikrein 3 (hk3). The function of PSA
is in the liquefaction of the seminal coagulum to allow for the
release of spermatozoa (3).
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PSA was established as a main biomarker of prostate cancer
(PCa) with its discovery in 1979. It became rapidly available
and was also a widely used diagnostic test in the early 1990s
(3). Currently, PSA is widely used for the detection or screen-
ing of PCa and for monitoring patients after treatment (4).
PCa is the second most common malignancy (after lung can-
cer) in men worldwide. Approximately 1,276,106 new cases
caused 358,989 deaths (3.8% of all deaths caused by cancer
in men) in 2018 (5). It has been reported that the incidence
of PCa was 191,054, and approximately 81,229 deaths were
recorded in Asian countries in 2012. In Yemen, as in other
countries in the Middle East, the incidence of PCa is low, but
the disease is being increasingly reported. The crude inci-
dence rate of PCa in Yemen was reported to be 0.9/100,000 in
2012 (6).
Diabetes has been linked to an increased risk of developing
cancer, including pancreas, liver, and breast cancer. How-
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ever, the connection between PCa and diabetes is currently
less understood (7). There are some epidemiological studies
on the relationship among diabetes, PCa risk and PSA. How-
ever, the results have often been discrepant. Several meta-
analyses have indicated that diabetes mellitus (DM) is asso-
ciated with a 9–16% decreased risk of PCa (8, 9). Diabetes is
a chronic health problem and is characterized by high blood
glucose levels, which result from defects in insulin produc-
tion, insulin action, or both (10). DM is an important pub-
lic health problem and the top four noncommunicable dis-
eases (NCDs), including cardiovascular disease, cancer, and
chronic respiratory disease. The prevalence of diabetes has
been gradually growing over the past few decades (9). World-
wide, an estimated 422 million adults were living with dia-
betes in 2014, compared to 108 million in 1980. The interna-
tional prevalence (age-standardized) of diabetes has nearly
doubled since 1980, rising from 4.7% to 8.5% in the adult
population. This reflects a rise in related risk factors such as
being overweight or obese. In the past, diabetes prevalence
has risen faster in countries with low- and middle-income
than in high-income nations (7). Diabetes caused 1.6 million
deaths in 2016. Almost half of all deaths attributable to high
blood glucose occur before the age of 70 (11). Several stud-
ies have reported that hyperglycemia and insulin resistance
are linked with physical inactivity, obesity, and poor diet, and
may be associated with hyperinsulinemia. The independent
presence and/or combination of these metabolic perturba-
tions may increase PCa risk (11).
However, several studies have determined that obese men
have lower serum PSA concentrations than nonobese men
(12, 13). Additionally, some reports found no relationship
between body mass index (BMI) and PSA level or percent
free PSA (14, 15). Nevertheless, few publications suggest that
recent-onset diabetes increases PCa risk (in line with a pos-
itive association of diabetes and colorectal cancer) but that
long-standing diabetes lowers PCa risk (16, 17). A study was
carried out in Egypt and included 501 men; 207 of them had
type 2 DM, and they were 55 and above years old. The results
showed that the mean PSA level in diabetic patients was 2.3
ng/ml, while the corresponding value for nondiabetic indi-
viduals was 3.5 ng/ml. Generally, a significant negative corre-
lation was found between the duration of DM treatment and
PSA values (18). A multiethnic prospective cohort study, in-
cluding 215,251 men aged 45-75 years at recruitment living
in Hawaii and Los Angeles county, reported a highly signifi-
cant association between type 2 diabetes status and PCa in-
cidence, with men with diabetes having an ∼20% lower risk
of developing PCa than nondiabetic men (19). Moreover, a
meta-analysis reported that diabetic patients have a statisti-
cally significant 9% decrease in the risk of developing carci-
noma of the prostate (20).
Although several studies (21-23) have been conducted to esti-
mate PSA levels in diabetic patients, the relationship between
PSA levels and DM is unclear and less understood. Some
studies have reported that patients with long-standing dia-
betes mellitus showed decreased PSA levels compared to in-
dividuals without diabetes. On the other hand, some stud-
ies reported that patients who had diabetic mellitus for five
years or more had a higher incidence of PCa than men with-
out diabetes (21-24). To the best of our knowledge, there is a
lack of information about PSA levels in diabetes mellitus and
between PSA levels and other variables, such as age, smok-
ing, and BMI; thus, this study investigated the relationships
between these variables and PSA levels in men from Aden,
Yemen. Therefore, this study was undertaken to measure PSA
levels in diabetic men in Aden, Yemen.
2. Methods
2.1. Study design and population
This cross-sectional study was carried out in four main
outpatient clinics in public hospitals in Aden Governorate,
Yemen (Al-Gamhourea, 22 May, Al-Sadaqah and Basuhaib),
among diabetic patients older than 30 years of age. The study
was conducted between July 2019 and October 2019. Two-
tailed α was used with a p value = 0.05 at a 95% confidence
interval (CI); therefore, Zα = 1.96 for all variables. To calcu-
late sample size, the prevalence of diabetes in Yemen, which
was approximately 10% with a degree of precision = 5 %) was
used.
n=z2pq/d2
Where, n is the sample size and z is the z statistic for a level of
confidence (e.g., for a level of confidence of 95%, the z-value=
1.96). p is the prevalence of DM, which was calculated based
on the prevalence reported in a previous study conducted in
Yemen (24, 25), which was 10.4%. Hence, the minimum sam-
ple size was calculated:
n=1.962(10.4)(89.6)/52 =143
The study excluded nondiabetic men; men younger than 30
years of age; patients with prostate cancer; and patients who
had undergone rectal biopsy, prostate massage rectal oper-
ation or transurethral resection of the prostate. Such condi-
tions were ascertained from the patients’ medical history.
2.2. Ethical consideration
The protocol of the study was approved by the Research and
Ethics Committee of the Faculty of Medicine, University of
Aden, Yemen (Research Code: REC- 57-2019). Before partici-
pation in the study and before we obtained participant data,
all respondents were fully informed that participation was
voluntary and that it was possible to withdraw from the re-
search without notice. Those who wished to participate were
asked to sign a consent form.
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2.3. Data collection method
Diabetic patients who consented to participate in the study
were administered a structured questionnaire that was de-
signed to gather information regarding sociodemographic
information. The questionnaire was first developed in En-
glish and then was translated into the Arabic language. So-
ciodemographic information included the patient’s age, mar-
ital status, education level, height and weight, family history
of diabetes, duration of the disease and type of antidiabetic
treatment. Body weight and height were measured, and BMI
was calculated (weight in kg/height in m2), which was cat-
egorized as underweight (<18.5), normal weight (BMI 18.5-
24.9), overweight (BMI 25–29.9), or obese (BMI≥30) (26). The
team explained the entire process to the patients and then
invited them to participate in the study. Then, written and
signed consent was collected. Blood was withdrawn after an
overnight fast (8-12 hours with no food or drink except for
water). A 5 ml venous blood sample was collected from re-
spondents by venipuncture, and 2 ml was transferred into
an ethylenediaminetetraacetic acid (EDTA) tube for the mea-
surement of glucose and spun at 3000 rpm for 5 min to obtain
plasma. The remaining blood (3 ml) was transferred into a
sterile gel tube and allowed to clot for the measurement of
PSA. The clotted blood sample was spun at 3000 rpm for 5
min, and the serum (the supernatant) was aliquoted, trans-
ferred into a labeled Eppendorf tube, and stored at -20◦C un-
til PSA determination.
FBG was analyzed using enzymatic methods (glucose oxi-
dase method) according to a commercial kit (Glucose Mono
Reagent From Atlas Medical) and assessed using spectropho-
tometric methods. The collected serum was tested for PSA
by using a commercial ELISA kit according to the manu-
facturer’s protocol (DRG International, Inc., United States of
America, Lot # RN-59574).
2.4. Statistical analysis
The data in an Excel file were imported into Statistical Pack-
age for Social Sciences (SPSS) (ver. 20.0 for Windows; SPSS
Chicago, IL, USA). The data were cleaned and checked thor-
oughly by another person to ensure correctness of the entries
before embarking upon analysis. The demographic charac-
teristics of the respondents were presented in percentages
and frequencies. BMI was calculated as the weight divided
by the height squared. Differences in means were assessed
using a t-test or ANOVA where applicable. Correlations be-
tween the serum PSA levels and FBG levels were examined
by Pearson’s correlation analysis. A p-value of less than 0.05
was considered to be significant.
3. Results
3.1. General characteristics of subjects
A total of 167 diabetic patients participated voluntarily in this
study and were interviewed face to face to complete the ques-
tionnaire about some demographic factors, and blood was
withdrawn from them to measure FBG and PSA levels. Af-
ter the removal of incomplete questionnaires and hemolyzed
blood samples, the respondent rate was 81.8%. Data from
145 patients were analyzed.
The age distribution of the respondents showed that the
most represented age group was the 50- to 59-year-old group
(n=49, 33.8%), while the least represented age group was the
70- to 79-year-old group (n=7, 4.8%). Approximately one-
third (n=50; 34.5%) of the respondents had a primary edu-
cation, 46 (31.7 %) had higher education, 45 (31.0%) had a
secondary education and 4 (2.8%) were uneducated. Regard-
ing marital status, the results indicated that an overwhelm-
ing number of the respondents (n=136, 93.7%), were married
and 4 (2.8%) were single, whereas 3 (2.1%) of the respondents
were divorced and 2 (1.4%) were widowers.
3.2. Physical and clinical characteristics of the
study population
The mean height of respondents was 169.70 ± 7.90 cm, while
the mean weight was 75.99± 16.09 kg. Of these patients,
11 (7.6%) were in the normal BMI range (BMI 18.5–24.9),
71 (49.0%) were classified as overweight (BMI 25.0–29.9), 21
(14.5%) (BMI ≥30) were obese, and 42 (28.9%) were classi-
fied as underweight (BMI <18.5) (Figure 4.4). With respect to
smoking status, the majority of respondents did not smoke
(n=111, 76.6%), whereas 34 (23.4%) smoked.
Nearly half of the respondents (70, 48.3%) reported a family
history of diabetes, and 21 (14.5%) respondents had a fam-
ily history of prostate disease. Current pharmacological ther-
apy consisted of oral hypoglycemic agents in more than half
of respondents (88, 60.7%). Ninety-six (66.2%) respondents
had been living with diabetes for less than 10 years, and only
10 (6.9%) respondents had been living with diabetes for less
than 30 years (Table 1).
3.3. Serum prostate-specific antigen levels in
diabetic patients according to age and clinical
characteristics
The mean fasting blood glucose (FBG) level of the respon-
dents ± the standard deviation (SD) was 209.8 ± 76.9 mg/dl
(range 70 – 459 mg/dl). However, the PSA concentration for
the respondents ranged from 1.50 to 4.45 ng/ml, and the
mean ± the SD was 2.56 ± 0.62 ng/ml.
Table 2 shows the PSA level (ng/ml) in diabetic patients ac-
cording to age, BMI and smoking. The PSA level was sig-
nificantly associated with age (p < 0.05). Regarding BMI,
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there was no significant difference in mean PSA levels among
the various BMI category groups (p > 0.05). With respect to
smoking status, the PSA level of men was significantly higher
in smoking patients (2.60±0.48 ng/ml) than in nonsmoking
patients (2.45±0.65 ng/ml) (p < 0.05).
PSA level (ng/ml) in diabetic patients according to type and
duration of diabetes is showed in Table 3. PSA levels were
not significantly different based on the duration of DM or the
type of diabetic treatment (p > 0.05).
3.4. The correlation between PSA levels and FBG
levels
The correlation between PSA levels and FBG levels among
the study population was determined using Pearson corre-
lation tests. PSA levels were not significantly correlated with
fasting blood glucose level (r= -0.07, p = 0.379).
4. Discussion
The study aimed to measure PSA levels among diabetic men
who had not previously been diagnosed with prostate cancer.
The findings suggested that PSA levels were significantly as-
sociated with age and smoking status, but not with BMI, the
type of diabetic treatment, the duration of diabetes, or with
FBG levels.
PSA has become the most useful serum tumor marker in ad-
dition to digital rectal examination (DRE) for the manage-
ment of PCa (27). However, an examination of the charac-
teristics of serum PSA levels in several populations could be
of great support for clinicians, as it would help guide PCa
screening practices and assess the response to therapy and
tumor progression (28, 29). To our knowledge, this is the first
study to estimate PSA levels among diabetic patients in our
community. A cross-sectional study was conducted among
diabetic patients older than 30 years of age in the city of Aden
to assess PSA levels. Serum from 145 diabetic patients was
collected after informed consent was obtained to examine
total PSA levels by ELISA.
4.1. PSA levels
Serum PSA levels vary among individuals from different re-
gions of the world; Asian men have lower levels than men
of European descent and African Americans (30-32). The
present study revealed that the mean PSA level was 2.5
ng/ml, which was higher than the mean reported among nor-
mal healthy Saudi men (1.24 ng/ml) (33), Iranian men (1.70
ng/ml) (34), Indian men (1.3 ng/ml) (31), Korean men (1.0
ng/ml) (35), Nigerian men (1.84 ng/ml) (36), Turkish men
(1.56 ng/ml) (37), African-American men (2.1 ng/ml), and
white American men (1.53 ng/ml) (38). These differences
may be due to differences in the characteristics of the study
population, the method of detection, and sample size. Our
results were close to the values reported in Iraq (2.6 ng/ml)
(39). Our results are lower than the finding in Egypt (3.5
ng/ml) (18). However, despite the growing awareness of the
importance of PSA for early PCa diagnosis, reference values
of serum PSA in Yemeni men have not yet been established.
Therefore, Yemen should establish its own reference ranges
because of the influence of environmental and genetic differ-
ences. On the Arab regional level, the mean PSA level in the
current study is markedly higher than that reported in several
studies among diabetic patients in Iraq (1.97 ng/ml) (39)and
Morocco (1.31 ng/ml)(40). Our finding was close to the value
of diabetic men in Egypt (2.3 ng/ml) (18).
Several studies found a lower serum PSA level among indi-
viduals with diabetes. A large population-based cohort study
in Germany showed that severe forms of diabetes were re-
lated with lower PSA levels (22). In addition, a study showed
that serum PSA levels were lower in patients with type 2 dia-
betes than in healthy men among Japanese males aged 40–79
years (21)). On the other hand, a study performed in Tai-
wan reported that the incidence of prostate cancer signifi-
cantly increased with age in both diabetic and nondiabetic
men (24). These differences may be attributed to environ-
mental influences, changes in hormonal parameters (andro-
gens, insulin, IGF-1, leptin, etc.), metabolic syndrome and
genetic differences (41). Wallner and his colleagues assessed
the associations between T2DM and changes in serum PSA
levels, and suggested that Caucasian men with T2DM experi-
enced smaller increases in serum PSA levels than those with-
out diabetes (42).
4.2. PSA levels and age
It has been reported that PSA concentration is age-
dependent and tends to increase with age because the
prostate enlarges with age and contains more PSA-producing
tissues (43). The current study revealed a significant associa-
tion between age and serum PSA levels (p<0.05), and the PSA
levels increased with age.
Our results are in line with those of previous reports which
stated that the PSA level increased with age with a signifi-
cant association (33),(34). It has been reported in Morocco
that the PSA level increases with age in diabetic patients
and is significantly lower in those aged 50-75 years (40). On
the other hand, Cvitkoviae and colleagues reported that the
values of PSA in diabetic subjects were less age-dependent
than those in nondiabetic subjects, mainly among elderly pa-
tients. These variations could be attributed to the increase
in prostate volume; the diminished capacity of the prostate
to produce PSA; or, because of the prostate’s decreased abil-
ity to preserve cell integrity, its increased permeability due to
the breakdown of normal physiological barriers, thereby al-
lowing PSA to leak into the general circulation (44-46).
Additionally, a study among diabetic men from Iraq showed
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Table 1: Clinical characteristics of the study population (n=145)
Variables No %




No treatment 8 5.5




Table 2: PSA level (ng/ml) in diabetic patients according to age, BMI and smoking
Variables n Mean ± SD P-value Test











Smoking status 0.035* T-test
Yes 34 3.04±0.42
No 111 2.88±0.27
*Significant p < 0.05; **Significant p < 0.001
that there was no significant association between serum
PSA level and age (37, 39). Nonetheless, Oesterling pro-
posed that the recommended age-specific reference ranges
for healthy persons based on Olmsted County, Minnesota,
data for serum PSA were 0–2.5 ng/ml, 0–3.5 ng/ml, 0–4.5
ng/ml, and 0–6.5 ng/ml for men aged 40–49, 50–59, 60–69,
and 70–79 years, respectively (43). In addition, a previous
study reported a higher age-specific PSA of 0.83, 1.23, 1.83,
and 2.31 ng/ml, for African American men aged 40–49, 50–59,
60–69, and 70–79 years, respectively (30). For Saudi Arabia,
men had PSA values of 0.87, 0.93, 1.17, 1.44, and 2.05 ng/ml,
for those aged 30-40, 41-50, 51-60, 61-70, and ≥71 years, re-
spectively (33). Our results indicated that the mean PSA level
in our group of Yemeni diabetic patients was lower than the
normal reference range, which is specific to healthy individ-
uals in different geographical areas.
4.3. PSA levels and BMI
Our study indicated that there was no significant association
between PSA levels and BMI. Our findings were consistent
with those of some previous reports ((34), (14, 15, 47)). On
the other hand, other studies reported that BMI was inversely
related with PSA levels (48-50), indicating an inverse relation-
ship between BMI and PSA levels, especially among 70- to
79-year-old Chinese men with a BMI >25.0. In addition, Price
and his colleagues found that obesity (BMI >30) was associ-
ated with decreased PSA levels in a multiethnic cohort of par-
ticipants (12). Kubota found an inverse but weak relationship
between BMI and PSA levels in Japanese participants from a
large cohort study based on health check-up data (51). They
ascribed this variation in men with a higher BMI as being due
to the larger plasma volumes, which could decrease serum
concentrations of soluble tumor markers (23, 50). Another
study found that obesity was possibly associated with a re-
duction in PSA levels (p=0.096) (22). A study reported that
PSA levels were increased among men with a normal BMI,
and there were no significant differences among BMI cat-
egories in diabetic patients (52). A study found that both
the overweight and obese BMI groups showed lower pre-
dicted PSA levels than the comparison group (BMI<25); how-
ever, it has been reported that diabetes and overweight BMI
were independently associated with lower PSA levels (48).
Several epidemiological studies have suggested that obesity
is associated with an increased risk for the development of
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Table 3: PSA level (ng/ml) in diabetic patients according to type of treatment and duration of diabetes
Variables PSA Test
n Mean ± SD P-value




No treatment 8 2.76±0.27




Level of Glucose (mg/dl)
Below 140 (normal) 28 2.64 ± 0.72 0.462 T-test
140 and more (not normal) 117 2.54 ± 0.59
prostate cancer (52, 53). In contrast, other studies have been
somewhat inconsistent, as some have suggested that there
was an association between obesity and prostate cancer that
may differ by tumor aggressiveness (54, 55), and others have
stated a protective effect of obesity (56, 57). Therefore, this
association remains controversial and may vary according
to population characteristics and could be due to the small
sample size or poor representations of study populations
(58).
4.4. PSA levels and diabetes duration
In the current study, there was no statistically significant as-
sociation between the duration of diabetes and PSA levels.
Our finding agrees with that of Muller et al., who reported
that PSA levels were not associated with the duration of dia-
betes (22). On the other hand, a study conducted in the USA
found an inverse association between diabetes duration and
PSA levels, and the predicted geometric mean PSA value was
low in men who were diagnosed with diabetes for more than
10 years previously (48).
4.5. PSA levels and the type of diabetic treatment
The findings of the current study showed that there was no
significant difference in PSA levels among diabetic patients
receiving different types of diabetic treatment. Our findings
seem to be in line with those of a previous report (23). More-
over, a cohort study reported that there was no evidence that
antidiabetic medications were associated with lower PSA lev-
els (59). In contrast, a study in Germany showed that PSA val-
ues were significantly reduced in men with insulin treatment
(p=0.006) and oral diabetic medication (p=0.030) (22). How-
ever, diabetic men who took medication appeared to have
lower PSA levels than diabetic men who did not take medi-
cation (48). Other studies have reported higher PSA concen-
trations among men using metformin (60, 61). Regarding in-
sulin use, significant differences in post-medication PSA lev-
els were detected for exposure within 6 months of PSA being
measured (59). However, differences in findings may be due
to variations in study design and comparison populations.
4.6. PSA levels and smoking status
The present study reported a significant association between
smoking status and PSA levels. In accordance with our find-
ings, Koc and colleagues reported that younger and older
smokers displayed higher PSA levels than nonsmokers, al-
though the difference was not statistically significant (62). In
contrast, Gray and colleagues have reported no difference in
PSA levels between smokers and nonsmokers (63). However,
a study of PSA levels in men over the age of 55 found that PSA
levels were significantly lower in smokers than in nonsmok-
ers in men over 55 (15, 64). Moreover, Li and colleagues found
significantly lower PSA levels in smokers than in nonsmokers
in men over 40 (65). However, previous studies reported that
the relationship between PSA levels and smoking is not yet
clearly established (62).
4.7. PSA levels and FBG levels
The findings of this study suggested that there was no corre-
lation between FBG levels and serum PSA levels. A study con-
ducted by Mohammad et al. showed a negative relationship
between serum PSA levels and FBG levels (66). In contrast,
Cvitkovic et al. reported a negative relationship between FBG
levels and serum PSA levels (44). Additionally, a study from
Iran reported that there was no significant relationship be-
tween serum PSA levels and FBG levels (34). They attributed
these variations to total testosterone levels in people with
type 2 diabetes being lower than those in healthy people, and
this differÂňence could be due to low levels of sex hormone
binding globÂňulin (SHBG) (34, 67).
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4.8. Study limitations
The main limitations of this study are due to financial con-
straints. This study did not include a large-scale population
or a control group (healthy people), and it did not go further
to include some important investigations, such as free PSA
levels, the free/total PSA ratio, HbA1c levels, as well as andro-
gen and testosterone levels. Additionally, a number of fac-
tors such as manipulations to measure prostate weight and
volume might affect PSA levels. In addition, information on
cycling and sexual intercourse was not revealed by the men
who participated in the study. It is possible that men with
underlying prostate disease could have been included in this
study, although we excluded subjects with evident prostate
disease. We did not consider types of oral diabetes medica-
tions in our analyses, although metformin and sulfonylurea
are the most common medications used in Yemen for the
treatment of diabetes. Another limitation was the lack of ad-
justment for other common medications, such as antihyper-
tensives, 5α-reductase inhibitors, and lipid-lowering medi-
cations, which may potentially affect PSA levels.
5. Conclusion
The current study revealed that PSA levels were significantly
associated with age and smoking status. No relaÂňtionship
was observed between PSA levels and BMI, the type of dia-
betic treatment, or FBG levels. Therefore, special considera-
tion should be warranted in the evaluation of PSA in elderly
diabetic patients, and further investigation is needed when
prostate cancer is suspected. PSA levels are affected by many
factors that may be unrelated to diabetes, including age and
smoking. Our results may help clinicians take these factors
into account when setting the PSA cutoff value at screening.
Further studies are needed to confirm our results and to ex-
plain the underlying variations.
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